Skip to content 
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | 20.46M | 31.89M | [{"date":"2024-12-31","value":64.15,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | 20.46M | 31.89M | [{"date":"2024-12-31","value":64.15,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Gross Margin | 100.00% | 100.00% | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Expenses | 217.40M | 266.96M | [{"date":"2024-12-31","value":81.44,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (196.94M) | (235.06M) | [{"date":"2024-12-31","value":-19693900000,"profit":false},{"date":"2025-12-31","value":-23506500000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 31.77M | 24.79M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":78.03,"profit":true}] | |||
| Pre-Tax Income | (181.17M) | (222.80M) | [{"date":"2024-12-31","value":-18117200000,"profit":false},{"date":"2025-12-31","value":-22280200000,"profit":false}] | |||
| Income Taxes | 212.00K | 163.00K | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":76.89,"profit":true}] | |||
| Income After Taxes | (181.38M) | (222.97M) | [{"date":"2024-12-31","value":-18138400000,"profit":false},{"date":"2025-12-31","value":-22296500000,"profit":false}] | |||
| Income From Continuous Operations | (181.38M) | (222.97M) | [{"date":"2024-12-31","value":-18138400000,"profit":false},{"date":"2025-12-31","value":-22296500000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (173.77M) | (203.15M) | [{"date":"2024-12-31","value":-17377100000,"profit":false},{"date":"2025-12-31","value":-20315400000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| GENB | |
|---|---|
| ROA (LTM) | -34.63% |
| ROE (LTM) | -81.72% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| GENB | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 50.39 |
| P/B | 0.00 |
| EV/R | 45.56 |
| EV/Ebitda | NM |
Generate Biomedicines, Inc. Common Stock (GENB) share price today is $12.12
Yes, Indians can buy shares of Generate Biomedicines, Inc. Common Stock (GENB) on Vested. To buy
Yes, you can purchase fractional shares of Generate Biomedicines, Inc. Common Stock (GENB) via the Vested app. You can start investing in Generate Biomedicines, Inc. Common Stock (GENB) with a minimum investment of $1.
You can invest in shares of Generate Biomedicines, Inc. Common Stock (GENB) via Vested in three simple steps:
The 52-week high price of Generate Biomedicines, Inc. Common Stock (GENB) is $16. The 52-week low price of Generate Biomedicines, Inc. Common Stock (GENB) is $11.
The price-to-earnings (P/E) ratio of Generate Biomedicines, Inc. Common Stock (GENB) is
The price-to-book (P/B) ratio of Generate Biomedicines, Inc. Common Stock (GENB) is 0.00
The dividend yield of Generate Biomedicines, Inc. Common Stock (GENB) is 0.00%
The market capitalization of Generate Biomedicines, Inc. Common Stock (GENB) is $1.59B
The stock symbol (or ticker) of Generate Biomedicines, Inc. Common Stock is GENB
Consider the share price of Generate Biomedicines, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Generate Biomedicines, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Generate Biomedicines, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Generate Biomedicines, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Generate Biomedicines, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Generate Biomedicines, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
